Special Issue

Deregulated Signaling Pathways and Innovative Therapeutic Approaches in Cancer

Message from the Guest Editors

A pleiad of deregulated molecular pathways leads to the genesis, promotion, progression, and finally metastasis of the cancer tissue. Nowadays, the recent advances in this field have offered key therapeutic approaches to halt or even, in some cases, eliminate the cancer cells. This Special Issue targets collecting new data from either side of research (molecular, biochemical, bioinformatics, meta-analysis, systemic review, preclinical data, and clinical data) related to the mechanism(s) of action of novel anti-cancer therapeutics. In addition, articles related to the potential druggable mechanisms of tumorigenesis and/or drug resistance are also well accepted. Our potential aim is to gather recent data on the molecular biology of cancer, with potentially significant impact on anti-cancer therapeutics. Both Special Issue Editors, and, are experienced at the molecular basis of cancer, signaling pathways, and metabolic profiles, as well as novel anticancer pharmacological approaches. Both Special Issue Editors welcome new submissions in this issue.

Guest Editors

Dr. Sofia Georgiou-Siafis

- 1. Laboratory of Hematology, University General Hospital of Larissa, Mezourlo, GR-41110 Larissa, Greece
- Laboratory of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Thessaly, GR-43100 Karditsa, Greece
 Faculty of Health and Rehabilitation Sciences, Metropolitan College,
- GR-41005 Larissa, Greece

Dr. Ioannis S. Pappas

Laboratory of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Thessaly, GR-43100 Karditsa, Greece

Deadline for manuscript submissions

25 May 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/259498

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

